[go: up one dir, main page]

NO20053348L - Farmasoytisk sammensetning for behandling av virusangrep. - Google Patents

Farmasoytisk sammensetning for behandling av virusangrep.

Info

Publication number
NO20053348L
NO20053348L NO20053348A NO20053348A NO20053348L NO 20053348 L NO20053348 L NO 20053348L NO 20053348 A NO20053348 A NO 20053348A NO 20053348 A NO20053348 A NO 20053348A NO 20053348 L NO20053348 L NO 20053348L
Authority
NO
Norway
Prior art keywords
pharmaceutical composition
treatment
hcv
compound
viral attacks
Prior art date
Application number
NO20053348A
Other languages
English (en)
Other versions
NO20053348D0 (no
Inventor
Takuo Tsukuda
Masahiro Aoki
Hideyuki Kato
Masayuki Sudoh
Miyako Masubuchi
Kenichi Kawasaki
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of NO20053348D0 publication Critical patent/NO20053348D0/no
Publication of NO20053348L publication Critical patent/NO20053348L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Farmasøytisk blanding til forebygging eller behandling av virale infeksjonssykdommer. Forbindelsen ifølge oppfinnelsen har ekstremt potent anti-HCV-aktivitet og HCV-vekstinhiberende effekt, og siden de også bare oppviser en mild cytotoksitet in vivo, er en farmasøytisk blanding som inneholder forbindelsen ifølge oppfinnelsen svært godt egnet som et anti-HCV preventivt/terapeutisk middel.
NO20053348A 2003-02-12 2005-07-11 Farmasoytisk sammensetning for behandling av virusangrep. NO20053348L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003034056 2003-02-12
JP2003272420 2003-07-09
PCT/JP2004/001498 WO2004071503A1 (ja) 2003-02-12 2004-02-12 ウイルス治療薬

Publications (2)

Publication Number Publication Date
NO20053348D0 NO20053348D0 (no) 2005-07-11
NO20053348L true NO20053348L (no) 2005-09-12

Family

ID=32871168

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053348A NO20053348L (no) 2003-02-12 2005-07-11 Farmasoytisk sammensetning for behandling av virusangrep.

Country Status (15)

Country Link
US (2) US7776918B2 (no)
EP (1) EP1593378B1 (no)
JP (1) JP3921227B2 (no)
KR (1) KR101071014B1 (no)
AU (1) AU2004211850B2 (no)
BR (1) BRPI0407140A (no)
CA (1) CA2515370C (no)
IL (1) IL169551A (no)
MX (1) MXPA05008507A (no)
MY (1) MY141506A (no)
NO (1) NO20053348L (no)
NZ (1) NZ542250A (no)
RU (1) RU2350600C2 (no)
TW (1) TWI335219B (no)
WO (1) WO2004071503A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2531790A1 (en) 2003-07-09 2005-01-20 Chugai Seiyaku Kabushiki Kaisha Compound having anti-hcv action and its production method
JP2006077004A (ja) * 2004-08-11 2006-03-23 Chugai Pharmaceut Co Ltd 抗ｈｃｖ作用を有する化合物およびそれを含む医薬組成物
JP4849622B2 (ja) * 2004-08-11 2012-01-11 中外製薬株式会社 Ｈｃｖ感染症を治療または予防するための薬剤
JPWO2006088071A1 (ja) * 2005-02-17 2008-07-03 中外製薬株式会社 抗ｈｃｖ作用を有する化合物の製造方法およびその中間体
WO2007000994A1 (ja) * 2005-06-28 2007-01-04 Chugai Seiyaku Kabushiki Kaisha 抗ｈｃｖ作用を有する化合物の製造方法
KR20090021163A (ko) 2006-05-16 2009-02-27 도쿄 메트로폴리탄 오거니제이션 포 메디칼 리서치 Ｈｃｖ 감염증을 치료 또는 예방하기 위한 의약 조성물
TW201010692A (en) * 2008-06-19 2010-03-16 Public Univ Corp Nagoya City Univ Pharmaceutical composition for treatment or prevention of hbv infection
US8957199B2 (en) 2008-11-26 2015-02-17 Chugai Seiyaku Kabushiki Kaisha Oligoribonucleotide or peptide nucleic acid capable of inhibiting activity of hepatitis C virus
JP2013121935A (ja) 2011-12-12 2013-06-20 Institute Of Microbial Chemistry 化合物、及び不斉合成反応
US9266853B2 (en) 2012-08-17 2016-02-23 Chugai Seiyaku Kabushiki Kaisha Orally available viridiofungin derivative possessing anti-HCV activity
JP5933867B1 (ja) * 2016-03-28 2016-06-15 公益財団法人微生物化学研究会 化合物、及び不斉合成反応
CN114105855B (zh) * 2020-08-31 2024-03-15 中国科学院大连化学物理研究所 一种在吲哚c2位引入异戊烯基的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU770012A1 (ru) * 1979-05-21 1982-01-23 Ордена Трудового Красного Знамени Институт Высокомолекулярных Соединений Ан Ссср D,L-или L-N-метакрилоилтриптофан в качестве мономера дл получени полимеров с ковалентно присоединенными триптофановыми группами
US5364948A (en) * 1991-08-02 1994-11-15 Merck & Co., Inc. Biologically active compounds isolated from aerobic fermentation of Trichoderma viride
EP0526936A3 (en) 1991-08-02 1993-05-05 Merck & Co. Inc. Cholesterol-lowering agents
US5503973A (en) 1992-05-29 1996-04-02 The Regents Of The University Of California Method for inhibition of viral morphogenesis
ES2209140T3 (es) * 1997-06-09 2004-06-16 Takara Bio Inc. Sustancias tkr2449 fisiologicamente activas, procedimientos para producir las mismas y microorganismo.

Also Published As

Publication number Publication date
CA2515370C (en) 2012-01-17
US7776918B2 (en) 2010-08-17
US20100274026A1 (en) 2010-10-28
JPWO2004071503A1 (ja) 2006-06-01
CA2515370A1 (en) 2004-08-26
TW200501940A (en) 2005-01-16
AU2004211850A2 (en) 2009-02-12
BRPI0407140A (pt) 2006-02-07
IL169551A (en) 2011-10-31
EP1593378A1 (en) 2005-11-09
MY141506A (en) 2010-05-14
NZ542250A (en) 2008-12-24
HK1095036A1 (zh) 2007-04-20
KR20050098929A (ko) 2005-10-12
EP1593378A4 (en) 2009-05-06
KR101071014B1 (ko) 2011-10-06
WO2004071503A1 (ja) 2004-08-26
TWI335219B (en) 2011-01-01
EP1593378B1 (en) 2013-09-25
NO20053348D0 (no) 2005-07-11
AU2004211850A1 (en) 2004-08-26
US20060217434A1 (en) 2006-09-28
MXPA05008507A (es) 2005-10-20
RU2350600C2 (ru) 2009-03-27
AU2004211850B2 (en) 2009-06-04
RU2005128297A (ru) 2006-02-27
JP3921227B2 (ja) 2007-05-30

Similar Documents

Publication Publication Date Title
CA2473070A1 (en) Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatites c virus infection
BRPI0415883A (pt) compostos e composições de nucleosìdeo para o tratamento de infecções virais
AU2002360592A8 (en) Inhibitors of hepatitis c virus
WO2005051980A8 (en) Depeptidized inhibitors of hepatitis c virus ns3 protease
PL376409A1 (en) Composition for the treatment of infection by flaviviridae viruses
WO2008079159A3 (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
IS7533A (is) Lifrarbólgu C-veirutálmar
WO2004041203A3 (en) Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
NO20052071L (no) Bezofuranforbindelser, preparater og metoder for behandling og forebygging av hepatitt C virale infeksjoner og relaterte sykdommer.
MY151199A (en) Substituted diphenyl heterocycles useful for treating hcv infection
WO2004002940A8 (en) Inhibitors of hcv ns5b polymerase
AU2003291885A1 (en) Compounds and methods for the treatment or prevention of flavivirus infections
AR030591A1 (es) Inhibidores de proteasa peptidomimetica
NO20042298L (no) Farmasoytiske preparater og deres anvendelser
WO2004112718A3 (en) Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
NO20053348L (no) Farmasoytisk sammensetning for behandling av virusangrep.
WO2004085682A3 (de) Caspase inhibitoren, insbesondere von caspase-3, zur behandlung von influenza
BR9810755A (pt) Terapia de bloqueio de cd 154 para a sìndrome inibidora de proteìna terapêutica
ATE458750T1 (de) Antivirale mittel zur behandlung, kontrolle und prävention von infektionen durch coronaviren
WO2004099165A3 (en) Heterocyclic compounds and hydro isomers thereof
DK1355906T3 (da) 2H-1-benzopyranderivater, fremgangsmåder til deres fremstilling og farmaceutiske sammensætninger indeholdende dem
WO2005084315A3 (en) Pyranoindole derivatives and the use thereof for the treatment of hepatitis c virus infection or disease
ATE373644T1 (de) N-substituierte 3-hydroxy-4-pyridinone und diese enthaltende pharmazeutika
BRPI0410967A (pt) compostos, composições e seus usos para o tratamento de infecções por vìrus da famìlia flaviviridae
WO2004078115A3 (en) Benzothiazole compounds, compositions and methods for treatment and prophylaxis of rotavirus infections and associated diseases

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application